CytoDyn (CYDY) Revenue (2021 - 2022)

CytoDyn's (CYDY) quarterly Revenue came in at $34000.0 in Q2 2022, down 84.89% on a QoQ basis from $225000.0 in Q4 2021.

Analysis

CytoDyn (CYDY) Revenue (2021 - 2022) Analysis & Trends

CytoDyn (CYDY) has 2 years of Revenue data on file, last reported at $34000.0 in Q2 2022.

Quarterly Revenue changed N/A year-over-year to $34000.0 in Q2 2022, while the trailing twelve-month figure through May 2022 was $300000.0 (changed N/A YoY) and the FY2022 annual result came in at $300000.0, changed N/A from the prior year.
Revenue fell to $34000.0 in Q2 2022, from $225000.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $225000.0 in Q4 2021 to a low of $34000.0 in Q2 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	86.04 Bn	78.05 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	63.70 Bn	58.52 Bn	1.37 Bn	1.52 Bn
4	Moderna	57.56 Bn	52.42 Bn	52.00 Mn	145.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-	-
6	BeOne Medicines	40.16 Bn	35.06 Bn	1.53 Bn	1.71 Bn
7	Alnylam Pharmaceuticals	35.63 Bn	32.32 Bn	992.69 Mn	1.29 Bn
8	Royalty Pharma	28.63 Bn	27.79 Bn	-	674.14 Mn
9	Insmed	27.73 Bn	26.57 Bn	358.27 Mn	425.49 Mn
10	CytoDyn	269.46 Mn	269.46 Mn	-	-

Historic Data

Download Data